All Stories

  1. The role of gender as a barrier to the professional development of psychiatrists
  2. Impact of adverse childhood experiences on educational achievements in young people at clinical high risk of developing psychosis
  3. Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis
  4. Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis
  5. Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis
  6. Dysregulated Lipid Metabolism Precedes Onset of Psychosis
  7. Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression
  8. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings
  9. The association between migrant status and transition in an ultra-high risk for psychosis population
  10. Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence
  11. Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people
  12. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis
  13. EEG Microstate Differences in Medicated vs. Medication-Naïve First-Episode Psychosis Patients
  14. Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study
  15. Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis
  16. Editorial
  17. Omega‐3 fatty acids and neurocognitive ability in young people at ultra‐high risk for psychosis
  18. EEG microstates as biomarker for psychosis in ultra-high-risk patients
  19. Prediction of clinical outcomes beyond psychosis in the ultra‐high risk for psychosis population
  20. Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
  21. Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?
  22. Anatomical integrity within the inferior fronto-occipital fasciculus and semantic processing deficits in schizophrenia spectrum disorders
  23. Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial
  24. Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis
  25. Dysregulated lipid metabolism precedes onset of psychosis in people at clinical high risk
  26. Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis
  27. Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes
  28. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis
  29. Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene–Environment Interactions study
  30. Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial
  31. Individualized prediction of psychosis in subjects with an at-risk mental state
  32. Predictors of study drop-out and service disengagement in patients at clinical high risk for psychosis
  33. An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium
  34. Clinical and functional ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis
  35. Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review
  36. Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk
  37. Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach
  38. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
  39. Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study
  40. Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis
  41. No associations between medial temporal lobe volumes and verbal learning/memory in emerging psychosis
  42. Correction
  43. Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?
  44. Estrogens and SERMS as adjunctive treatments for schizophrenia
  45. O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY
  46. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial
  47. Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status
  48. Bride price payment and women’s autonomy: Findings from qualitative interviews from Nigeria
  49. WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women
  50. Dynamic prediction of transition to psychosis using joint modelling
  51. Voxel-Based Morphometry Correlates of an Agitated-Aggressive Syndrome in the At-Risk Mental State for Psychosis and First Episode Psychosis
  52. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium
  53. Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression
  54. The relationship between negative symptoms and cognitive functioning in patients at clinical high risk for psychosis
  55. Sexually dimorphic subcortical brain volumes in emerging psychosis
  56. Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)?
  57. Exploring the predictive power of the unspecific risk category of the Basel Screening Instrument for Psychosis
  58. Clinical trajectories in the ultra-high risk for psychosis population
  59. Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients
  60. NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course
  61. Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in at-risk mental state and first-episode psychosis
  62. Disorganized Gyrification Network Properties During the Transition to Psychosis
  63. Sex and gender differences in schizophrenic psychoses—a critical review
  64. Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling
  65. The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding
  66. T212. THE INTRINSIC ORGANIZATION OF SYMPTOMS MARKS TRANSITION FROM HIGH-RISK STATE TO EARLY PSYCHOSIS: A PHENOMENOLOGICAL CONNECTIVITY STUDY
  67. O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL
  68. S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING
  69. T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY
  70. T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION
  71. Abnormal brain connectivity during error-monitoring in the psychosis high-risk state
  72. Letter from the Editor-in-Chief
  73. Impact on the Onset of Psychosis of a Polygenic Schizophrenia-Related Risk Score and Changes in White Matter Volume
  74. The Frankfurt Complaint Questionnaire for self-assessment of basic symptoms in the early detection of psychosis-Factor structure, reliability, and predictive validity
  75. Gender differences in first self‐perceived signs and symptoms in patients with an at‐risk mental state and first‐episode psychosis
  76. Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women
  77. Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients
  78. Age-related brain structural alterations as an intermediate phenotype of psychosis
  79. Duration of untreated psychosis/illness and brain volume changes in early psychosis
  80. Patient-Identified Priorities Leading to Attempted Suicide
  81. Screening for Adult Attention-Deficit/Hyperactivity Disorder in a Psychiatric Outpatient Population with Specific Focus on Sex Differences
  82. Alpha oscillations underlie working memory abnormalities in the psychosis high-risk state
  83. Prediction of conversion to psychosis in individuals with an at-risk mental state
  84. Outcome of individuals “not at risk of psychosis” and prognostic accuracy of the Basel Screening Instrument for Psychosis (BSIP)
  85. Comorbidities in Patients with an At-risk Mental State and First Episode Psychosis
  86. Estradiol Production Suppressed by Prolactin in at-risk Mental State and First Episode Psychosis Female Patients? Preliminary Results
  87. Long-term rates of remission and late psychotic transition of individuals at risk for psychosis
  88. Stigma in early detection of psychosis: Subjective experiences of those concerned
  89. The Current European Status
  90. The Relationship Between Negative Symptoms and Cognitive Functioning in Patients with an at Risk Mental State for Psychosis
  91. Verbal Learning and Memory in At-risk Mental State and First Episode Psychosis Patients and Their Correlates to Brain Structural Alterations
  92. Working Together for Early Detection of Psychosis
  93. Autonomy and Reproductive Rights of Married Ikwerre Women in Rivers State, Nigeria
  94. Letter from the Editor-in-Chief
  95. Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting
  96. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders
  97. Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses
  98. Sex and gender differences in mental disorders
  99. Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis
  100. Altered Insular Function during Aberrant Salience Processing in Relation to the Severity of Psychotic Symptoms
  101. Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders
  102. Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis
  103. Pourquoi et comment soigner plus précocement les troubles psychotiques ?
  104. Alterations in the hippocampus and thalamus in individuals at high risk for psychosis
  105. Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis
  106. Increased superior frontal gyrus activation during working memory processing in psychosis: Significant relation to cumulative antipsychotic medication and to negative symptoms
  107. Impact of polygenic schizophrenia-related risk and hippocampal volumes on the onset of psychosis
  108. Does menopausal transition really influence mental health? Findings from the prospective long-term Zurich study
  109. High time for a paradigm shift in psychiatry
  110. Neural oscillations in antipsychotic-naïve patients with a first psychotic episode
  111. Longitudinal determinants of client treatment satisfaction in an intensive first-episode psychosis treatment programme
  112. The role of vulnerability factors in individuals with an at-risk mental state of psychosis
  113. Early psychosis in young women
  114. Sex and gender differences in schizophrenic psychoses
  115. Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk
  116. Appropriateness of Care and Joint Decision-Making Strategies
  117. The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis
  118. Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naïve at-risk patients
  119. Abnormal functional integration of thalamic low frequency oscillation in the BOLD signal after acute heroin treatment
  120. At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction
  121. Correlations between self-rating and observer-rating of psychopathology in at-risk mental state and first-episode psychosis patients: influence of disease stage and gender
  122. Early detection of psychosis: helpful or stigmatizing experience? A qualitative study
  123. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders
  124. Modulation of motivational salience processing during the early stages of psychosis
  125. Depression in der Peripartalzeit – Diagnostik, Therapie und Prophylaxe
  126. Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers
  127. EPA guidance on the early detection of clinical high risk states of psychoses
  128. EPA guidance on the early intervention in clinical high risk states of psychoses
  129. Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution
  130. Das Basler Interview für Psychosen (BIP): Struktur, Reliabilität und Validität
  131. Perinatal mental health service provision in Switzerland and in the UK
  132. Autism Spectrum Disorders
  133. Therapist-client sex in psychotherapy: attitudes of professionals and students towards ethical arguments
  134. Sex Differences in Cognitive Functioning in At-Risk Mental State for Psychosis, First Episode Psychosis and Healthy Control Subjects
  135. Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing
  136. Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication
  137. Brain Diffusion Changes in Emerging Psychosis and the Impact of State-Dependent Psychopathology
  138. Früherkennung und Frühintervention bei beginnenden Psychosen
  139. Comorbidity of Mental and Physical Disorders
  140. Normalizing effect of heroin maintenance treatment on stress-induced brain connectivity
  141. Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis
  142. Acute Effects of Heroin on Negative Emotional Processing: Relation of Amygdala Activity and Stress-Related Responses
  143. Evidence for an agitated–aggressive syndrome predating the onset of psychosis
  144. Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state
  145. Detecting the Psychosis Prodrome Across High-Risk Populations Using Neuroanatomical Biomarkers
  146. Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations
  147. Effects of heroin
  148. Poster #S162 DEFICITS IN FINE MOTOR SKILLS IN EMERGING PSYCHOSIS
  149. Poster #M222 PSYCHOSIS EARLY DETECTION: HELPFUL OR STIGMATIZING EXPERIENCE? A QUALITATIVE PILOT STUDY
  150. Poster #S147 EYE MOVEMENT ABNORMALITIES IN ADULTS WITH AN AT-RISK MENTAL STATE FOR PSYCHOSIS
  151. HELP-SEEKING AND PATHWAYS TO CARE IN THE EARLY STAGES OF PSYCHOSIS: RESULTS FROM THE FEPSY STUDY
  152. Poster #T189 DEVIANT NEURAL OSCILLATIONS AND LAGGED PHASE SYNCHRONICITY IN PATIENTS WITH AN AT-RISK MENTAL STATE FOR PSYCHOSIS
  153. Poster #M40 THE RELATION OF ABNORMAL BRAIN CONNECTIVITY AND PSYCHIATRIC SYMPTOM EXPRESSION IN SUBJECTS AT HIGH-RISK FOR PSYCHOSIS
  154. Poster #T180 THE COURSE OF COGNITIVE FUNCTIONING IN CLINICAL HIGH RISK AND FIRST-EPISODE PSYCHOSIS INDIVIDUALS
  155. Poster #S109 THE BASEL INTERVIEW FOR PSYCHOSIS: STRUCTURE, RELIABILITY AND VALIDITY
  156. Poster #T220 TRANSITION AND PSYCHOSIS RELATED HEMODYNAMIC CORRELATES OF MOTIVATIONAL SALIENCE PROCESSING
  157. THE PSYCHOSIS HIGH RISK STATE: IS IT VALID?
  158. Schmidt a psychosis
  159. Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis
  160. The attenuated psychosis syndrome in DSM-5
  161. Are neurological soft signs pre-existing markers in individuals with an at-risk mental state for psychosis?
  162. Violence against women and mental health
  163. Cannabis use and brain structural alterations of the cingulate cortex in early psychosis
  164. Boothe B, Riecher-Rössler A (Hrsg) (2013) Frauen in Psychotherapie. Grundlagen – Störungsbilder – Behandlungskonzepte
  165. Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders
  166. Comentario de libro
  167. Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis
  168. S.10.03 Hyperprolactinemia in drug-naïve first-episode patients: data from EUFEST
  169. P.1.i.025 Abnormal brain functioning during salience processing in patients with schizophrenic psychosis
  170. P.6.d.001 Inhibition-specific prefrontal connectivity after an acute dose of heroin
  171. Reduction in Cerebral Perfusion after Heroin Administration: A Resting State Arterial Spin Labeling Study
  172. Brain Connectivity Abnormalities Predating the Onset of Psychosis
  173. Sollen junge Menschen mit Psychoserisikosyndrom behandelt werden?
  174. Häusliche Gewalt bei Frauen einer Kriseninterventionspopulation - Formen der Gewalt und Risikofaktoren
  175. Cannabis use and cognitive functions in at-risk mental state and first episode psychosis
  176. Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study
  177. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial
  178. Suicide attempts in the county of Basel: results from the WHO/EURO Multicentre Study on Suicidal Behaviour
  179. Vorhersage von Psychosen durch stufenweise Mehrebenenabklärung - Das Basler FePsy(Früherkennung von Psychosen)-Projekt
  180. Inferior Frontal Cortex Modulation with an Acute Dose of Heroin During Cognitive Control
  181. Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis
  182. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis
  183. Acute effects of heroin on emotions in heroin‐dependent patients
  184. Duration of untreated psychosis and cognitive functioning
  185. Acute Effects of Intravenous Heroin on the Hypothalamic-Pituitary-Adrenal Axis Response
  186. Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial
  187. Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial
  188. Violence against Women and Mental Health
  189. Association of Frontal Gray Matter Volume and Cerebral Perfusion in Heroin Addiction: A Multimodal Neuroimaging Study
  190. The Psychosis High-Risk State
  191. 2710 – Gender differences in the psychopathology of emerging psychosis
  192. Do Subjects at Clinical High Risk for Psychosis Differ from those with a Genetic High Risk? - A Systematic Review of Structural and Functional Brain Abnormalities
  193. Help-seeking and pathways to care in the early stages of psychosis
  194. Hippocampal volume in subjects at high risk of psychosis: A longitudinal MRI study
  195. Can cognitive deficits facilitate differential diagnosis between at‐risk mental state for psychosis and depressive disorders?
  196. Kann Cannabis das Risiko für schizophrene Psychosen erhöhen?
  197. Whither the Attenuated Psychosis Syndrome?
  198. P.2.a.018 Actigraphically measured poor sleep is related to cortisol awakening response and parenting stress in postpartum depression
  199. P.1.e.014 Hippocampal volume in individuals with an at-risk mental state: a longitudinal magnetic resonance imaging analysis
  200. Effects of Cannabis Use on Human Brain Structure in Psychosis: A Systematic Review Combining In Vivo Structural Neuroimaging and Post Mortem Studies
  201. Distinguishing Prodromal From First-Episode Psychosis Using Neuroanatomical Single-Subject Pattern Recognition
  202. Group Treatment for Depression in Mothers of Young Children Compared to Standard Individual Therapy
  203. Priorities for research in child maltreatment, intimate partner violence and resilience to violence exposures: results of an international Delphi consensus development process
  204. Cost of attempted suicide: a retrospective study of extent and associated factors
  205. Poster #54 PITUITARY GLAND VOLUME IN INDIVIDUALS WITH AN AT-RISK MENTAL STATE: A LONGITUDINAL MRI ANALYSIS
  206. Poster #43 NEGATIVE SYMPTOMS IN THE EARLY STAGES OF PSYCHOSIS ARE ASSOCIATED WITH CHANGES IN THE CINGULATE
  207. Poster #52 DURATION OF UNTREATED ILLNESS/PSYCHOSIS AND COGNITIVE FUNCTIONING
  208. Poster #236 LONGITUDINAL CHANGES OF PSYCHOPATHOLOGICAL SYMPTOMS IN AT-RISK MENTAL STATE (ARMS) INDIVIDUALS WITHOUT TRANSITION TO PSYCHOSIS
  209. Poster #56 INSULAR VOLUME ABNORMALITIES ASSOCIATED WITH DIFFERENT TRANSITION PROBABILITIES TO PSYCHOSIS – A VOXEL-BASED MORPHOMETRY STUDY
  210. Poster #51 CANNABIS USE AND BRAIN STRUCTURAL ALTERATIONS OF CINGULATE CORTEX AND HIPPOCAMPUS IN FIRST EPISODE PSYCHOSIS PATIENTS AND AT RISK MENTAL STATE SUBJECTS
  211. Poster #127 DO NEUROLOGICAL SOFT SIGNS IN AT-RISK MENTAL STATE INDIVIDUALS PREDICT TRANSITION TO FIRST EPISODE PSYCHOSIS?
  212. First self‐perceived signs and symptoms in emerging psychosis compared with depression
  213. Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study
  214. Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?
  215. Cingulate Volume Abnormalities in Emerging Psychosis
  216. Attempted Suicide in Immigrants from Turkey: A Comparison with Swiss Suicide Attempters
  217. The Impact of Diacetylmorphine on Hypothalamic-Pituitary-Adrenal Axis Activity and Heroin Craving in Heroin Dependence
  218. Themenschwerpunkt „Women‘s Mental Health“
  219. Depression und Psychose in der Menopause - kann eine Hormontherapie hilfreich sein?
  220. Insular volume abnormalities associated with different transition probabilities to psychosis
  221. Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective
  222. Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study
  223. Different duration of at‐risk mental state associated with neurofunctional abnormalities. A multimodal imaging study
  224. Missbrauch in therapeutischen Beziehungen
  225. Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)
  226. Sexual Dysfunction in First-Episode Schizophrenia Patients
  227. Neuroanatomical Abnormalities That Predate the Onset of Psychosis
  228. Patienten mit intensivpflichtigen medikamentösen Suizidversuchen – Risikoprofil und Verlauf
  229. A Randomized, Double-Blind, Placebo-Controlled Study of Light Therapy for Antepartum Depression
  230. Stress reactivity in patients with drug dependence and personality disorders
  231. Missbrauch in therapeutischen Beziehungen
  232. 5 Psychosen in Schwangerschaft und Stillzeit
  233. 10 Psychopharmakotherapie in Schwangerschaft und Stillzeit
  234. 8 Depressionen in der Postpartalzeit
  235. 1 Depressionen in der Schwangerschaft
  236. 13 Lichttherapie bei Depressionen in der Schwangerschaft
  237. 12 Gruppentherapie für Mütter mit Depressionen
  238. Pituitary volume increase during emerging psychosis
  239. Depression in der Schwangerschaft
  240. Depression in der frühen Mutterschaft
  241. EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis
  242. The Self-screen-Prodrome as a short screening tool for pre-psychotic states
  243. Hyperprolactinaemia in early psychosis—not only due to antipsychotics
  244. Domestic violence against women: Definitions, epidemiology, risk factors and consequences
  245. Neuroimaging predictors of transition to psychosis—A systematic review and meta-analysis
  246. Neural effects of heroin — Relation to anxiety stress
  247. Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study
  248. Prospects for the classification of mental disorders in women
  249. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)
  250. QEEG SPECTRAL POWER AND NEGATIVE SYMPTOMS IN THE DETECTION OF BEGINNING PSYCHOSIS
  251. VERBAL EPISODIC MEMORY IN FIRST EPISODE AND AT RISK MENTAL STATE FOR PSYCHOSIS PATIENTS COMPARED TO DEPRESSIVE PATIENTS AND HEALTHY CONTROLS
  252. COMPARISON OF CLINICAL ROUTINE EEG AND QUANTITATIVE EEG IN FIRST EPISODE OF PSYCHOSIS AND AT-RISK MENTAL STATE INDIVIDUALS
  253. Antipsychotic Drug Treatment in First-Episode Psychosis
  254. P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis
  255. Schizophrenia in women
  256. Estrogens and Gonadal Function in Schizophrenia and Related Psychoses
  257. S25-03 - At Risk Mental State for Psychosis: Clinical Features and Natural Course
  258. PW01-21 - Poor Sleep is Related to Parenting Stress and Impaired Postpartum Bonding in Depressed Mothers
  259. Negative symptoms in neuroleptic-naïve patients with first-episode psychosis correlate with QEEG parameters
  260. Efficacy of Using Cognitive Status in Predicting Psychosis: A 7-Year Follow-Up
  261. Prediction of Caseness for Mental Pathology in Swiss Conscripts: The Self-Screen Prodrome
  262. Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study
  263. Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia
  264. 04. Differential correlation of EEG power and negative symptoms in patients with and without transition to psychosis
  265. 06. QEEG spectral power density changes in the early course of schizophrenia
  266. Antipsychotics and hyperprolactinaemia: pathophysiology, clinical significance, clarification and therapy
  267. Schwangerschaftsdepression und deren Behandlung
  268. Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?
  269. The Effects of Antipsychotics on the Brain: What Have We Learnt from Structural Imaging of Schizophrenia? – A Systematic Review
  270. Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie
  271. Intervention in Individuals at Ultra-High Risk for Psychosis
  272. Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)
  273. Correction
  274. The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?
  275. EEG: a helpful tool in the prediction of psychosis
  276. „Selbstscreen-Prodrom” – Ein Selbstbeurteilungsinstrument zur Früherkennung von psychischen Erkrankungen und Psychosen
  277. Psychotic Disorders and Menopause: The Untold Story
  278. Can Cortical Thickness Asymmetry Analysis Contribute to Detection of At-Risk Mental State and First-Episode Psychosis?: A Pilot Study
  279. Schizophrenia and Motherhood
  280. Treatment Options in Depression During the Postpartum
  281. Suizidversuche in der ersten und zweiten Generation der ImmigrantInnen aus der Türkei
  282. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis
  283. Elternschaft und Belastungserleben: Psychometrische Überprüfung des Parenting-Stress-Index (PSI) an einer deutschsprachigen Stichprobe
  284. Psychische Störungen in Zeiten hormoneller Umstellung bei Frauen – Eine selektive Übersicht
  285. STRATEGIES FOR IMPROVING THE PREDICTION OF PSYCHOSIS
  286. GRAY MATTER ABNORMALITIES AND COGNITIVE FUNCTION IN SUBJECTS AT RISK FOR PSYCHOSIS: LONGITUDINAL PERSPECTIVES
  287. CAN CORTICAL THICKNESS ANALYSIS IN AT RISK MENTAL STATE CONTRIBUTE TO EARLY DETECTION OF PSYCHOSIS?
  288. THE NEURAPRO (NORTH AMERICA, EUROPE, AUSTRALIA PRODROME) STUDY: A MULTICENTER RCT OF TREATMENT STRATEGIES FOR SYMPTOMATIC PATIENTS AT ULTRA-HIGH RISK FOR PROGRESSION TO SCHIZOPHRENIA AND RELATED DISORDERS. DESIGN AND STUDY PLAN
  289. Das Basel Screening Instrument für Psychosen (BSIP): Entwicklung, Aufbau, Reliabilität und Validität
  290. Insular pathology in the at-risk mental state
  291. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
  292. Nützen Behandlungsempfehlungen in psychiatrischen versicherungsrechtlichen Gutachten?
  293. Anterior and posterior cingulum abnormalities in the prodromal phase of schizophrenia
  294. 183 – The Basel Screening Instrument for Psychosis (BSIP) – predicitive validity and interrater reliability
  295. Anterior cingulate pathology in the prodromal stage of schizophrenia
  296. Geschlechtsspezifische Aspekte in der Psychotherapie
  297. Autorinnen und Autoren
  298. Screening Partnergewalt
  299. Neuropsychological deficits in individuals with an at risk mental state for psychosis — Working memory as a potential trait marker
  300. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence
  301. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis
  302. The role of medication in suicide attempts in Switzerland
  303. Früherkennung schizophrener Psychosen bei Männern und Frauen
  304. Aneurysms of Pericallosal Cerebral Artery Haemorrhage with Consecutive Psychosis
  305. Cavum septum pellucidum in patients with first episode psychosis and individuals at high risk of psychosis
  306. Psychotic experiences in the general population: A twenty-year prospective community study
  307. Regional Gray Matter Volume Abnormalities in the At Risk Mental State
  308. Indication and impact of mentoring models
  309. Prospects for the classification of mental disorders in women
  310. Association of regional grey matter abnormalities with cognitive functions in the at risk mental state
  311. Cognitive capability of individuals at risk with and without transition to psychosis
  312. Akute Psychose
  313. Schizophrenie und verwandte Erkrankungen
  314. Akut- und Notfallpsychiatrie – Wo werden die Betroffenen behandelt?
  315. TC12C THE FEPSY (EARLY DETECTION OF PSYCHOSIS) STUDY – TRANSITION RATES AND PREDICTORS OF PSYCHOSIS
  316. 0352 FIRST SIGNS AND SYMPTOMS IN INDIVIDUALS AT RISK FOR PSYCHOSIS AND PATIENTS WITH A FIRST EPISODE OF PSYCHOSIS
  317. WC4G GREY MATTER ABNORMALITIES IN PEOPLE WITH AN AT RISK MENTAL STATE — CROSS-SECTIONAL AND LONGITUDINAL DATA
  318. Oestrogen-A Protective Factor in Schizophrenia?
  319. The Basel early‐detection‐of‐psychosis (FEPSY)‐study – design and preliminary results
  320. Radiological findings in individuals at high risk of psychosis
  321. Early detection and treatment of schizophrenia: how early?
  322. Postpartale Depression
  323. Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable
  324. N. Bergemann and A. Riecher-Rössler, Editors, Estrogen Effects in Psychiatric Disorders, Springer-Verlag GmbH, Wien, Austria (2005) 291 pages, 40 figures, ISBN 3-211-40485-6.
  325. Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia
  326. Buchbesprechung
  327. The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
  328. Size of burden of schizophrenia and psychotic disorders
  329. Werden psychisch Kranke zu schnell in die Rente „abgeschoben”?
  330. Estrogen Effects in Psychiatric Disorders
  331. Group Psychotherapy for Depression in Early Stages of Motherhood
  332. Diagnostic Classification of Perinatal Mood Disorders
  333. Chronic subdural hemorrhage in a patient with suspected schizophrenia prodrome
  334. Geschlechtersensible Betreuungsansätze
  335. Behandlungsprobleme bei schizophrenen Störungen
  336. Late-Onset Schizophrenia Versus Paranoid Psychoses: A Valid Diagnostic Distinction?
  337. Postpartum depression: do we still need this diagnostic term?
  338. Gruppentherapie bei Depression in der frühen Mutterschaft
  339. Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: preliminary results from the Basel early detection of psychosis study - Früherkennung von Psychosen (FEPSY)
  340. Östrogene und gonadale Achse Implikationen für die Therapie von Frauen mit Schizophrenien
  341. Oestrogens and schizophrenia
  342. Controversial issues in climacteric medicine III: Hormone replacement therapy in climacteric and aging brain
  343. Oestrogens and schizophrenia - Introduction
  344. Oestrogen effects in schizophrenia and their potential therapeutic implications - Review
  345. Östrogene und Schizophrenie - Patientinnen an der Schnittstelle zwischen Psychiatrie und Gynäkologie
  346. Estrogen effects in schizophrenia — brief update and potential therapeutic implications
  347. Group therapy for mothers with depression
  348. Sexualhormone und Psyche
  349. Innentitel
  350. 1 Einfluss von Östrogenen und Gestagenen auf das Zentralnervensystem
  351. 2 Das prämenstruelle Syndrom
  352. 5 Östrogene und schizophrene Psychosen
  353. 4 Hormonelle Aspekte bei affektiven Störungen, Angstund Zwangserkrankungen
  354. 6 Einfluss von Psychopharmaka auf Reproduktion und Kontrazeption
  355. 7 Sachverzeichnis
  356. Einführung: Sexualhormone und Psyche – Ergebnisse des 2. Interdisziplinären Frankfurter Gesprächs zur Kontrazeption
  357. 3 Postpartale Depression und depressive Zustände im Klimakterium sowie unter der Hormonsubstitution
  358. Schizophrenie und Wahn im höheren und hohen Lebensalter
  359. Geschlechtsunterschiede bei Schizophrenie - m�gliche therapeutische Implikationen
  360. Gruppentherapie f�r depressive M�tter
  361. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry
  362. Book Reviews
  363. Psychische Erkrankungen bei Frauen - einige Argumente für eine geschlechtersensible Psychiatrie und Psychotherapie/ Mental diseases in women - some arguments for a gender-sensitive psychiatry and psychotherapy
  364. Association between oestradiol and puerperal psychosis
  365. Computer-assisted self-monitoring by patients with schizophrenia
  366. Traditional Methodology and Outcome Assessment in Studies on the Course of Schizophrenia
  367. Visual cognitive deficits in patients with borderline personality disorder
  368. The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective
  369. The ABC schizophrenia study: a preliminary overview of the results
  370. Gonadal function and its influence on psychopathology
  371. Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle
  372. Causes and Consequences of the Gender Difference in Age at Onset of Schizophrenia
  373. What do we really know about late-onset schizophrenia?
  374. 50 Jahre nach Manfred Bleuler
  375. Psychische Störungen und Erkrankungen nach der Entbindung
  376. Changing patterns of mental health care in Germany
  377. Late onset schizophrenia — A valid entity? An empirical study on risk factors, psychopathology and course
  378. Case management for schizophrenic patients at risk for rehospitalization: A case control study
  379. Symptom Assessment in Casenotes and the Clinical Diagnosis of Schizophrenia
  380. Late-onset Schizophrenia and Late Paraphrenia
  381. Onset and Early Course of Schizophrenia
  382. Further evidence for a specific role of estradiol in schizophrenia?
  383. Validation of Danish case register diagnosis for schizophrenia
  384. Wilhelm Griesinger and the Concept of Community Care in 19th-Century Germany
  385. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia
  386. Organic factors and the clinical features of late paranoid psychosis: a comparison with Alzheimer's disease and normal ageing
  387. The Epidemiology of Early Schizophrenia
  388. Wirken Östrogene antipsychotisch?
  389. Can Estradiol Modulate Schizophrenic Symptomatology?
  390. Higher morbidity risk for schizophrenia in males: Fact or fiction?
  391. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia
  392. Schizophrenia and oestrogens — is there an association?
  393. Compulsory admission of psychiatric patients – an international comparison
  394. Einfluß des Menstruationszyklus auf die therapeutische Ansprechbarkeit schizophrener Patientinnen
  395. Schizophrenie — Eine Krankheit verliert ihre Dämonie
  396. The influence of age and sex on the onset and early course of schizophrenia
  397. Does case management reduce the rehospitalization rate?
  398. Die Zwangseinweisung psychiatrischer Patienten im nationalen und internationalen Vergleich - Häufigkeiten und Einflußfaktoren
  399. Is age of onset in schizophrenia influenced by marital status?
  400. First onset and early symptomatology of schizophrenia
  401. IRAOS: an instrument for the assessment of onset and early course of schizophrenia
  402. Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle
  403. Effects of the Menstrual Cycle on the Therapeutic Response in Schizophrenia
  404. Effects of the menstrual cycle on therapeutic response in schizophrenic patients
  405. Interview "Onset of Schizophrenia"
  406. Geschlechtsunterschiede bei schizophrenen Erkrankungen
  407. Factors influencing compulsory admission of psychiatric patients
  408. Différences selon le sexe dans l’âge d’apparition, la symptomatologie et l’évolution de la schizophrénie
  409. 15 Jahre Psychiatriereform in der Bundesrepublik Deutschland
  410. Community care in child psychiatry
  411. Gender Differences in Age at Onset and Course of Schizophrenic Disorders
  412. How does gender influence age at first hospitalization for schizophrenia? A transnational case register study
  413. Schizophrenia — a disease of young single males?
  414. Central Institute of Mental Health, Mannheim, West Germany
  415. Was ist postpartale Depression?
  416. Estrogens and Schizophrenia
  417. Early Detection of Psychosis - Helpful or Stigmatizing Experience for Those Concerned?
  418. Early Detection and Intervention in Psychosis
  419. Neurocognition and Motor Functioning in the Prediction of Psychosis